Therapeutic fibrinolysis has been dominated by the experience with tissue-type plasminogen activator (t-PA), which proved little better than streptokinase in acute myocardial infarction. In contrast, endogenous fibrinolysis, using one-thousandth of the t-PA concentration, is regularly lysing fibrin and induced Thrombolysis In Myocardial Infarction flow grade 3 patency in 15% of patients with acute myocardial infarction. This efficacy is due to the effects of t-PA and urokinase plasminogen activator (uPA). They are complementary in fibrinolysis so that in combination, their effect is synergistic. Lysis of intact fibrin is initiated by t-PA, and uPA activates the remaining plasminogens. Knockout of the uPA gene, but not the t-PA gene, inhibited fibrinolysis. In the clinic, a minibolus of t-PA followed by an infusion of uPA was administered to 101 patients with acute myocardial infarction; superior infarct artery patency, no reocclusions, and 1% mortality resulted. Endogenous fibrinolysis may provide a paradigm that is relevant for therapeutic fibrinolysis. tissue-type plasminogen activator (t-PA) and urokinase plasminogen activator (uPA). They exist in both single-chain and plasmin-cleaved 2-chain forms.
A n occlusive intravascular thrombus triggers the cardiovascular diseases that are the leading causes of death and disability worldwide.
The only pharmacological means to remove the thrombus is fibrinolysis. There are 2 plasminogen activators in the blood responsible for fibrinolysis:
tissue-type plasminogen activator (t-PA) and urokinase plasminogen activator (uPA). They exist in both single-chain and plasmin-cleaved 2-chain forms.
With t-PA, both forms have the same activity (1), whereas the single-chain form of uPA is a proenzyme (pro-uPA) and the 2-chain form is an active enzyme (2-chain uPA, the enzymatic form of uPA [tc-uPA]) (2).
The fibrin specificity of t-PA is mediated by high fibrin affinity (3,4), which promotes plasminogen activating activity about a thousand-fold (5). It was the first fibrin-specific plasminogen activator, and became the first recombinant protein on the market (6). The clinical experience with t-PA in acute myocardial infarction (AMI), ischemic stroke, and venous thromboembolism has been extensive. As a result, t-PA became essentially equated with fibrinolysis, as shown by it frequently not being identified specifically in publications on clinical fibrinolysis.
The anticipated benefits of t-PA were never fulfilled, and it has been largely replaced by percutaneous coronary intervention (PCI) as the treatment of choice for AMI in urban centers in the United States, although it is still used in rural areas too far from a catheterization facility. As pre-treatment, or facilitated PCI, t-PA significantly increased both thrombotic and hemorrhagic complications of PCI (7), and its use has been discouraged. In ischemic stroke, t-PA is used in only about 5% of patients (8) , and in venous thromboembolism, a hemorrhagic risk has limited its use to patients with hemodynamic instability due to the emboli (9) .
The enzymatic form of uPA, tc-uPA, has been known since the 1940s as a nonspecific activator, like streptokinase (SK), which caused bleeding complications. The single-chain uPA proenzyme, pro-uPA, was not identified and isolated until 1980 (10) . It has no fibrin affinity, but is nevertheless fibrin specific (11).
Being a proenzyme, it remains inert in blood until it reaches a clot, a pharmacologically advantageous property. Unfortunately, this property is undermined by dose-dependent plasma instability, because it activates plasma plasminogen at certain therapeutic concentrations, and plasmin converts prouPA to tc-uPA. For example, in a study where pro-uPA and SK were compared in AMI, bleeding complications occurred in 14% of the pro-uPA patients, of whom 4% required transfusions and 2 patients had an intracranial hemorrhage (ICH) (12) . At physiological and lower therapeutic concentrations, pro-uPA is stable in plasma and is an essential component of the endogenous fibrinolytic system.
FIBRINOLYSIS WITH t-PA
The U.S. patients were required before a significant p value was reached for a mortality difference (13) (14) (15) . This was in only 1 of 4 groups in the last trial, in which an accelerated rate of t-PA infusion induced a significant 30-day mortality difference (6.3% vs. 7.0%) (15) . Also unexpected was the finding that the ICH rate was significantly higher with t-PA than SK, despite the nonspecific and indirect mode of action of SK. These results did not stand up to a Bayesian analysis, which concluded, "the clinical superiority of t-PA over SK remains uncertain" (16) .
As heralded by these trials, t-PA's limited efficacya 16 AE 10% reocclusion rate (17)-prothrombotic hematologic effects, such as thrombin generation and platelet activation (18) (19) (20) (21) (22) , and bleeding side effects, such as ICH, led to alternative therapies.
PCI VERSUS t-PA
In a review of 23 PCI trials involving 7,739 patients, 3,867 were randomized to treatment with fibrinolysis A special challenge for primary PCI treatment is reducing the time to reperfusion. Reduction in AMI mortality is greatest if reperfusion is accomplished within 1 to 2 h of symptom onset (27) , and in patients who received reperfusion treatment within 70 min of symptom onset, the mortality was 1.2% (28) . In animal models, the longer the coronary occlusion, the less salvageable myocardium remains (29) . Therefore, pre-treatment was tested.
FACILITATED PCI WITH t-PA
Although t-PA pre-treatment doubled the number of patients with initial TIMI flow grade 3 patency, the final TIMI flow grade 3 patency rates did not differ in the 2 groups (89% vs. 88%), consistent with t-PA's significant rethrombosis rate (17) . In addition, more bleeding, reinfarctions, and strokes occurred with facilitated PCI (30) . By contrast, with pro-uPA, neither a prothrombotic effect nor reocclusions were found in AMI (31) , suggesting that the complications were related to t-PA rather than to fibrinolysis.
It was concluded that t-PA facilitated PCI offered no benefit, an outcome lamented in a commentary in a prominent journal as "Facilitated angioplasty:
paradise lost" (32) , because there is no alternative to shorten the time to reperfusion.
Interestingly, these studies found that in 15% of patients with ST-segment elevation myocardial infarction, TIMI flow grade 3 was already found at the time of the primary PCI (33), and these patients fared significantly better (24, 25) . This illustrates the efficacy of endogenous fibrinolysis in which the t-PA concentration is $1,000-fold lower than the therapeutic one.
t-PA FIBRINOLYSIS IN ISCHEMIC STROKE
In ischemic stroke, a t-PA dose reduction was required due to a 20% symptomatic ICH incidence when the usual AMI dose was used (34) . As a result, the t-PA recanalization decreased 30% to 40%, making it ineffective for larger thrombi in proximal occlusions (35, 36) . Even at the reduced dose, the symptomatic ICH rate was 6% to 7% (37).
In the largest trial, 1,500 patients per group were randomized to t-PA or standard care and treated within 6 h. The proportion of patients alive and living independently at 6 months was 37% with t-PA and 35% for the controls. Although insignificant, a secondary ordinal analysis found a significant (p < 0.001) favorable shift in the functional score in the t-PA-treated patients, but more patients died with t-PA in the first 7 days (11% vs. 7%; p ¼ 0.001) (38) . The authors concluded that early treatment with t-PA should be PULMONARY EMBOLISM, DEEP VEIN THROMBOSIS, AND LIMB ISCHEMIA PULMONARY EMBOLISM. Because anticoagulants provide effective and safe treatment for the majority of patients, fibrinolysis is currently limited to hemodynamically unstable patients at risk of death (9) . In a study of 1,006 such patients randomized to anticoagulants or fibrinolysis with mutant t-PA, fibrinolysis reduced the risk of hemodynamic decompensation and death (2.6% vs. 5.6%), but increased the risk of major hemorrhage (6.3% vs.1.2%) and stroke (2.4% vs. 0.2%). It was concluded that, "great caution is warranted when considering current fibrinolytic therapy for this indication" (43) . Catheter placement within the thrombus is a prerequisite for this indication, and a positive guidewire test has been found to be a favorable prognostic sign for lysis (45) . Successful lysis (>75% thrombus removal)
was achieved in 72% of 119 patients; reocclusions occurred within 30 days in 13%, amputations were required in 6%, and life-threatening complications, including bleeding and stroke, occurred in 12% (46) .
Bleeding complications remain the main deterrent to more widespread use of fibrinolysis for these indications.
LESSONS FROM ENDOGENOUS FIBRINOLYSIS
There is a noteworthy contrast between the limited therapeutic efficacy of t-PA and its efficacy in the endogenous fibrinolytic system, especially because most of the t-PA in blood is in an inactive complex with its inhibitor, plasminogen activator inhibitor-1 Third, during pro-uPA plasminogen activation, prouPA is reciprocally activated by plasmin to the enzyme, tc-uPA (54), which promotes and completes fibrinolysis. Therefore, uPA has 2 fibrinolytic functional states that contribute to fibrinolysis and explain its dominance because t-PA has only 1 functional state (1), consistent with the gene knockout findings (51,52). In addition, this uPA property is also in keeping with a study comparing t-PA and pro-uPA clot lysis rates; that of pro-uPA was consistently twice that of t-PA (55). 10-mg bolus of t-PA was administered to initiate fibrinolysis, which was followed by an infusion of 40 mg/h of pro-uPA (50% of the standard AMI infusion rate) for 90 min. This proved to be too much t-PA because it caused some bleeding, as in the 2 studies described. Therefore, the t-PA dose was reduced to in plasma that induce 25% lysis in 5 h, and clot lysis when these same doses are combined.
In combination they induced 100% clot lysis. pro-uPA ¼ proenzyme urokinase plasminogen activator; t-PA ¼ tissue-type plasminogen activator.
5 mg (5% of the standard AMI dose) for the remaining 91 patients, with the same pro-uPA infusion, and there were no further bleeding episodes.
A TIMI flow grade 3 patency of the infarct artery at 90 min occurred in 60% of patients increasing to 82%
at 24 h. No reocclusions or strokes and only 1 death occurred in the study (62) . These results compare very favorably with the best of the t-PA trials (GUSTO) in which the TIMI flow grade 3 patency at 90 min was 54% and decreased to 45% at 24 h, reflecting t-PA's reocclusion rate; there were 1.5% strokes and 6.3% mortality (Figure 2 ) (63).
CENTRAL ILLUSTRATION Fibrinolysis and Bleeding by t-PA and pro-uPA
Gurewich, V. J Am Coll Cardiol. 2016;68 (19) :2099-106.
(Top) Fibrinolysis is initiated by t-PA, which binds to its binding site on intact fibrin (D-domain) and activates the fibrin-bound plasminogen at that site to plasmin. This initiates fibrin degradation by plasmin and creates 2 additional plasminogen binding sites, the first of which, on the fibrin E-domain, induces a special plasminogen conformation that enables pro-uPA itself to activate this plasminogen to plasmin (long arrow). Plasmin induces reciprocal activation of pro-uPA to tc-uPA, which then activates the remaining plasminogen and completes fibrinolysis. (Bottom) Bleeding: hemostatic fibrin is intact fibrin and, therefore, it contains the same t-PA and plasminogen binding sites that are on the fibrin D-domain shown in the top panel. As a result, hemostatic fibrin is vulnerable to lysis by therapeutic doses of t-PA.
High-dose pro-uPA activates plasma plasminogen and plasmin activates pro-uPA, generating more plasmin. pro-uPA ¼ proenzyme urokinase plasminogen activator;
tc-uPA ¼ 2-chain urokinase plasminogen activator, the enzymatic form of uPA; t-PA ¼ tissue-type plasminogen activator; uPA ¼ urokinase plasminogen activator. Pro-uPA is inactivated by the clotting enzyme thrombin (64); thus, its activity was destroyed inadvertently in many fibrinolysis studies in which lysis was preceded by thrombin clotting, giving the impression that only t-PA was involved in intravascular fibrinolysis. This concept was reinforced by the finding that uPA binds to a cell-surface uPA receptor, and is responsible for extravascular plasminogen activation important for cell migration. It was concluded that uPA was an extravascular plasminogen activator (65), a concept that has tended to persist (66) .
Much evidence to the contrary has had little effect on this concept, including the finding that a uPA cellsurface receptor knockout had no measurable effect on fibrinolysis by uPA, contrary to expectations (50) .
Finally, because most of the uPA is located on the surface of platelets (67, 68) and monocytes (69), rather than free in the plasma, it has often gone undetected. All of these pro-uPA properties help to explain why its essential role in fibrinolysis has been overlooked.
CONCLUSIONS
The 2 natural fibrin-dependent plasminogen activa- 
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